After fatal cases of drug reaction with eosinophilia and systemic symptoms and severe inflammatory brain disorders, e.g. anti-NMDA-encephalitis and anti-GFAP-IgG associated encephalitis, daclizumab was finally withdrawn from the market [8, 32, 43, 47]. Here, GFAP is linked to encephalitis.